- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07806474
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
Clinical Efficacy and Safety of Two Food Supplements on Hair Health in Caucasian Male Subjects With Androgenic Alopecia : a Multicentric, Randomised, Double-blind, Placebo-controlled Clinical Study
The goal of this clinical trial is to evaluate the efficacy and safety of two different formulations of a food supplement on hair health in healthy Caucasian male subjects aged 35 to 65 years with mild to moderate androgenetic alopecia. The main questions it aims to answer are:
- Whether the two formulations improve hair growth and reduce hair loss after 42 and 84 days, as assessed by phototricogram parameters.
- Whether the two formulations improve hair brightness, and colour lightness after 42 and 84 days, as assessed by spectrophotometer/colorimeter.
Researchers will compare two active supplement groups and a placebo group to determine whether the active products improve objective hair parameters and perceived hair quality.
Participants will:
- be randomized to one of three groups : Active 1, Active 2 or Placebo;
- take one capsule daily at breakfast for 84 days;
- attend clinical visits at baseline, Day 42, and Day 84;
- undergo hair assessments including pull test, phototrichogram, and spectrophotometer/colorimeter measurements;
- complete a self-assessment questionnaire at follow-up visits;
- be monitored for safety and tolerability throughout the study.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Jessica Lacetera
- 전화번호: +39 0382 25504
- 이메일: jessica.lacetera@complifegroup.com
연구 장소
-
-
Cosenza
-
Rende, Cosenza, 이탈리아
- Nutratech S.r.l. - Via Francesco Todaro 20/22
-
-
Ferrare
-
Ferrara, Ferrare, 이탈리아
- Complife Italia S.r.l. - Via Mortara 171
-
-
Milan
-
Garbagnate Milanese, Milan, 이탈리아
- Complife Italia S.r.l. - Via Signorelli 159
-
Milan, Milan, 이탈리아
- Complife Italia S.r.l. - Piazzale Siena 11
-
-
Pavia
-
Biella, Pavia, 이탈리아
- Complife Italia SRL - Corso San Maurizio 25
-
San Martino Siccomario, Pavia, 이탈리아
- Complife Italia S.r.l. - Via Monsignor Angelini 21
-
연락하다:
- Jessica Lacetera
- 전화번호: +39 0382 25504
- 이메일: jessica.lacetera@complifegroup.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Healthy male subjects
- Subjects of Caucasian ethnicity
- Subjects aged between 35 and 65 years (extremes included)
- Subjects with mild to moderate androgenetic alopecia, corresponding to the grade II to III vertex on Hamilton-Norwood scale
- Subjects with hair that is at least 5-7 cm long
- Subjects with visible grey or white hair
- Subjects registered with national health service
- Subjects certifying the truthfulness of the personal data disclosed to the Principal Investigator or designated personnel
- Subjects able to understand the language used in the investigation center and the information given by the Principal Investigator or designated personnel
- Subjects able to respect the instructions given by the Principal Investigator or designated personnel as well as able to respect the study constraints and specific requirements
- Subjects who commit not to change their daily routine or lifestyle during the study*
- Subjects on stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least one month without any changes expected or planned during the study
Subjects informed about the test procedures who have signed a consent form and privacy agreement
- Subjects are asked not to change their usual hair hygiene and styling products (such as shampoo, conditioner, hair gel, hairspray, etc.) throughout the study
Exclusion Criteria:
- Subjects who do not meet the inclusion criteria
- Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the Principal Investigator considers dangerous to the subject or incompatible with the requirements of the study **
- Subjects participating or planning to participate in other clinical trials
- Subjects who participated in a similar study without respecting an adequate washout period (at least one month)
- Subjects that have food intolerances or food allergies to ingredients of the study product
- Subjects under pharmacological treatments that are considered incompatible with the study requirement by the Principal Investigator ***
- Subjects who are currently using food supplement(s) and/or products with the same activity as the study product, or who haven't observed an adequate washout period (at least one month)
- Subjects admitted to a health or social facility
- Subjects planning a hospitalization during the study
- Subjects not able to be contacted in case of emergency
- Subjects deprived of freedom by administrative or legal decision or under guardianship
- Subjects who have or have had a history of alcohol or drug addiction
Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)
Including oncological diseases, diabetes, autoimmune diseases, acute inflammatory diseases, ongoing infectious diseases, and alopecia areata.
- Including corticosteroid drugs, biological drugs, and cytostatic drugs.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Active product 1
hard shell capsule containing green tea leaf extract (Camellia sinensis (L.) Kuntze, Theaceae), bamboo shoot extract (Bambusa vulgaris Schrad., Poaceae), and selenium-enriched yeast (Saccharomyces cerevisiae) and maltodextrin
|
one capsule per day during breakfast with water for 84 days
|
|
활성 비교기: Active product 2
hard shell capsule containing grape seed extract (Vitis vinifera L., Vitaceae), bamboo shoot extract (Bambusa vulgaris Schrad., Poaceae), and selenium-enriched yeast (Saccharomyces cerevisiae) and maltodextrin
|
one capsule per day during breakfast with water for 84 days
|
|
위약 비교기: Placebo
hard shell capsule containing maltodextrin
|
one capsule per day during breakfast with water for 84 days
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in anagen hair density
기간: 42 and 84 days
|
Number of hairs in anagen phase per cm² and proportion (in %) using phototricogram (TrichoScan)
|
42 and 84 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Total number of hair in anagen phase
기간: 42 and 84 days
|
= (Anagen hair after supplement use x scalp surface) - (Anagen hair before supplement use x scalp surface) where the scalp surface is 580 cm2.
|
42 and 84 days
|
|
Change in telogene hair density
기간: 42 and 84 days
|
Number of hairs in telogen phase per cm² and proportion (in %) using phototricogram (TrichoScan)
|
42 and 84 days
|
|
Number of hair protected against falling out (HPF)
기간: 42 ans 84 days
|
(TEAF x SH) - (TEBE x SH) where: TEAF is the number of telogen hair after supplement use ; TEBE is the number of telogen hair before product use; SH is the head surface (580cm2). |
42 ans 84 days
|
|
Change in total hair density
기간: 42 and 84 days
|
Number of total hairs per cm² using phototricogram (TrichoScan)
|
42 and 84 days
|
|
Change in hair brightness
기간: 42 and 84 days
|
Hair brightness is measured on 5 points near the hairline using a spectrophotometer/colorimeter CM 700D (Konica-Minolta).
The measured parameter is the 8° gloss value (average value of the 5 measures).
|
42 and 84 days
|
|
Change in hair colour lightness
기간: 42 and 84 days
|
Hair color lightness is measured on 5 points near the hairline using a spectrophotometer/colorimeter CM 700D (Konica-Minolta).
The measured parameter is the L* parameter (average value of the 5 measures) indicating the hair color lightness (i.e.
lighter or darker hair).
|
42 and 84 days
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Self-assessment questionnaire
기간: 42 and 84 days
|
Subjects are asked to reply to a self-assessment questionnaire to assess the efficacy perceived and the pleasantness of the product.
Responses are provided spontaneously, without external influence.
|
42 and 84 days
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Enza Cestone, Dr, Complife Italia Srl
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- EC_0000367/2026
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .